Perspectives on Payment Policies for Gene Therapies

Tuesday, November 5 | 9 a.m.–5 p.m. | The Westin City Center, Washington, D.C.


This program will address the status of legislative and regulatory solutions to the primary challenges in paying for gene therapies for different payer types (Medicaid, Medicare, and commercial payers), as well as the current state of Medicaid reimbursement policies for these therapies.

Objectives:

  1. Discuss recent progress in efforts to enable and utilize novel payment models for gene therapies
  2. Explore the status of Medicaid policies for gene therapies and opportunities for enhancing reimbursement mechanisms
  3. Identify the implications of recent decisions on Medicare coverage and reimbursement of CAR T-cell therapies

Full Agenda

Value of Gene Therapy & Significance of the Issues
9-10:35 a.m.

Advances in Novel Payment Solutions for Public & Private Payors
10:50 a.m. - 12:15 p.m.

  • Rob Osborne—Updates on Outcomes-Based and Innovative Payment Solutions
    Vice President of Trade Relations, Accredo Specialty Pharmacy and CuraScript SD
  • Tresja Bolt—Novel Payment Approaches: The Experience from Europe
    Head of European Government Affairs and Policy, bluebird bio
  • Dan Mytelka—Managing Gene Therapies: The Orphan Reinsurer and Benefit Manager (ORBM)
    Director of Policy and Simulations, MIT NEWDIGS
  • Panel Q&A
    Moderator: Janet Lambert, CEO, Alliance for Regenerative Medicine

Legislative Solutions: Novel Payment Mechanisms for Gene Therapies
1:15-2 p.m.

  • Anne Dwyer, J.D.
    Senior Health Counsel, Senate Committee on Finance
  • Stuart Portman
    Health Policy Advisor, Senate Committee on Finance
  • Panel Q&A
    Moderator: Mark Battaglini, J.D., Vice President, Global Government Affairs & Public Policy, bluebird bio

Deep Dive I: Perspectives on State and Federal Medicaid Policies
2-3:30 p.m.

Deep Dive II: A Fresh Look at Medicare Reimbursement Policies
3:45-5 p.m.

2020

ASGCT Policy Summit

September 23-25, 2020